{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,3]],"date-time":"2026-09-03T18:02:40Z","timestamp":1788458560411,"version":"build-2803163510"},"reference-count":29,"publisher":"MDPI AG","issue":"10","license":[{"start":{"date-parts":[[2022,9,30]],"date-time":"2022-09-30T00:00:00Z","timestamp":1664496000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Pharmaceutics"],"abstract":"<jats:p>Model-informed precision dosing (MIPD) can aid dose decision-making for drugs such as gentamicin that have high inter-individual variability, a narrow therapeutic window, and a high risk of exposure-related adverse events. However, MIPD in neonates is challenging due to their dynamic development and maturation and by the need to minimize blood sampling due to low blood volume. Here, we investigate the ability of six published neonatal gentamicin population pharmacokinetic models to predict gentamicin concentrations in routine therapeutic drug monitoring from nine sites in the United State (n = 475 patients). We find that four out of six models predicted with acceptable levels of error and bias for clinical use. These models included known important covariates for gentamicin PK, showed little bias in prediction residuals over covariate ranges, and were developed on patient populations with similar covariate distributions as the one assessed here. These four models were refit using the published parameters as informative Bayesian priors or without priors in a continuous learning process. We find that refit models generally reduce error and bias on a held-out validation data set, but that informative prior use is not uniformly advantageous. Our work informs clinicians implementing MIPD of gentamicin in neonates, as well as pharmacometricians developing or improving PK models for use in MIPD.<\/jats:p>","DOI":"10.3390\/pharmaceutics14102089","type":"journal-article","created":{"date-parts":[[2022,10,10]],"date-time":"2022-10-10T01:21:07Z","timestamp":1665364867000},"page":"2089","update-policy":"https:\/\/doi.org\/10.3390\/mdpi_crossmark_policy","source":"Crossref","is-referenced-by-count":11,"title":["Evaluating and Improving Neonatal Gentamicin Pharmacokinetic Models Using Aggregated Routine Clinical Care Data"],"prefix":"10.3390","volume":"14","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-7396-7958","authenticated-orcid":false,"given":"Dominic M. H.","family":"Tong","sequence":"first","affiliation":[{"name":"InsightRX, San Francisco, CA 94104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3053-1251","authenticated-orcid":false,"given":"Jasmine H.","family":"Hughes","sequence":"additional","affiliation":[{"name":"InsightRX, San Francisco, CA 94104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ron J.","family":"Keizer","sequence":"additional","affiliation":[{"name":"InsightRX, San Francisco, CA 94104, USA"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1968","published-online":{"date-parts":[[2022,9,30]]},"reference":[{"key":"ref_1","first-page":"w13873","article-title":"Recommendations for Term and Late Preterm Infants at Risk for Perinatal Bacterial Infection","volume":"143","author":"Stocker","year":"2013","journal-title":"Swiss Med. Wkly."},{"key":"ref_2","doi-asserted-by":"crossref","first-page":"1006","DOI":"10.1542\/peds.2012-0541","article-title":"Management of Neonates with Suspected or Proven Early-Onset Bacterial Sepsis","volume":"129","author":"Polin","year":"2012","journal-title":"Pediatrics"},{"key":"ref_3","doi-asserted-by":"crossref","first-page":"33","DOI":"10.1038\/ki.2010.337","article-title":"New Insights into the Mechanism of Aminoglycoside Nephrotoxicity: An Integrative Point of View","volume":"79","author":"Quiros","year":"2011","journal-title":"Kidney Int."},{"key":"ref_4","doi-asserted-by":"crossref","first-page":"S145","DOI":"10.1093\/infdis\/124.Supplement_1.S145","article-title":"Possible Nephrotoxicity of Gentamicin","volume":"124","author":"Schultze","year":"1971","journal-title":"J. Infect. Dis."},{"key":"ref_5","doi-asserted-by":"crossref","first-page":"S148","DOI":"10.1093\/infdis\/124.Supplement_1.S148","article-title":"Renal Insufficiency Associated with Gentamicin Therapy","volume":"124","author":"Wilfert","year":"1971","journal-title":"J. Infect. Dis."},{"key":"ref_6","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1159\/000244391","article-title":"Risk Factors of Sensorineural Hearing Loss in Preterm Infants","volume":"71","author":"Borradori","year":"1997","journal-title":"Neonatology"},{"key":"ref_7","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1007\/s00228-008-0599-y","article-title":"Clinical Pharmacokinetics of Aminoglycosides in the Neonate: A Review","volume":"65","author":"Pacifici","year":"2009","journal-title":"Eur. J. Clin. Pharmacol."},{"key":"ref_8","doi-asserted-by":"crossref","first-page":"71","DOI":"10.2165\/00003088-200948020-00001","article-title":"Therapeutic Drug Monitoring of Aminoglycosides in Neonates","volume":"48","author":"Touw","year":"2009","journal-title":"Clin. Pharmacokinet."},{"key":"ref_9","doi-asserted-by":"crossref","first-page":"785","DOI":"10.1002\/psp4.12353","article-title":"Model-Informed Precision Dosing at the Bedside: Scientific Challenges and Opportunities","volume":"7","author":"Keizer","year":"2018","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_10","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1111\/bcp.12444","article-title":"Population Pharmacokinetic Study of Gentamicin in a Large Cohort of Premature and Term Neonates: Population Pharmacokinetics of Gentamicin in Newborns","volume":"78","author":"Fuchs","year":"2014","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_11","doi-asserted-by":"crossref","first-page":"4869","DOI":"10.1128\/AAC.00577-16","article-title":"Development and Evaluation of a Gentamicin Pharmacokinetic Model That Facilitates Opportunistic Gentamicin Therapeutic Drug Monitoring in Neonates and Infants","volume":"60","author":"Germovsek","year":"2016","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_12","doi-asserted-by":"crossref","first-page":"1584","DOI":"10.1002\/jcph.1479","article-title":"Population Pharmacokinetic Modeling of Gentamicin in Pediatrics","volume":"59","author":"Wang","year":"2019","journal-title":"J. Clin. Pharmacol."},{"key":"ref_13","doi-asserted-by":"crossref","first-page":"e01304-16","DOI":"10.1128\/AAC.01304-16","article-title":"Population Pharmacokinetics and Dosing Considerations for Gentamicin in Newborns with Suspected or Proven Sepsis Caused by Gram-Negative Bacteria","volume":"61","author":"Bijleveld","year":"2017","journal-title":"Antimicrob. Agents Chemother."},{"key":"ref_14","doi-asserted-by":"crossref","first-page":"2643","DOI":"10.1007\/s11095-014-1361-z","article-title":"Simultaneous Pharmacokinetic Modeling of Gentamicin, Tobramycin and Vancomycin Clearance from Neonates to Adults: Towards a Semi-Physiological Function for Maturation in Glomerular Filtration","volume":"31","author":"Allegaert","year":"2014","journal-title":"Pharm. Res."},{"key":"ref_15","doi-asserted-by":"crossref","first-page":"372","DOI":"10.1093\/jac\/dkl244","article-title":"Population Pharmacokinetics of Gentamicin in Premature Newborns","volume":"58","author":"Garcia","year":"2006","journal-title":"J. Antimicrob. Chemother."},{"key":"ref_16","doi-asserted-by":"crossref","first-page":"659","DOI":"10.1111\/jcpt.12850","article-title":"A Review of Population Pharmacokinetic Models of Gentamicin in Paediatric Patients","volume":"44","author":"Crcek","year":"2019","journal-title":"J. Clin. Pharm. Ther."},{"key":"ref_17","doi-asserted-by":"crossref","first-page":"233","DOI":"10.1002\/cpt.2088","article-title":"Continuous Learning in Model-Informed Precision Dosing: A Case Study in Pediatric Dosing of Vancomycin","volume":"109","author":"Hughes","year":"2021","journal-title":"Clin. Pharmacol. Ther."},{"key":"ref_18","doi-asserted-by":"crossref","first-page":"888","DOI":"10.3389\/fphar.2020.00888","article-title":"Assessment of a Model-Informed Precision Dosing Platform Use in Routine Clinical Care for Personalized Busulfan Therapy in the Pediatric Hematopoietic Cell Transplantation (HCT) Population","volume":"11","author":"Shukla","year":"2020","journal-title":"Front. Pharmacol."},{"key":"ref_19","doi-asserted-by":"crossref","first-page":"185","DOI":"10.1002\/psp4.12745","article-title":"A Continued Learning Approach for Model-Informed Precision Dosing: Updating Models in Clinical Practice","volume":"11","author":"Maier","year":"2022","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_20","unstructured":"Bauer, R.J. (2011). NONMEM Users Guide: Introduction to NONMEM 7.2.0, ICON Development Solutions."},{"key":"ref_21","doi-asserted-by":"crossref","unstructured":"Bonate, P.L. (2011). Pharmacokinetic-Pharmacodynamic Modeling and Simulation, Springer. [2nd ed.].","DOI":"10.1007\/978-1-4419-9485-1"},{"key":"ref_22","doi-asserted-by":"crossref","first-page":"6","DOI":"10.1038\/psp.2012.4","article-title":"Basic Concepts in Population Modeling, Simulation, and Model-Based Drug Development","volume":"1","author":"Mould","year":"2012","journal-title":"CPT Pharmacomet. Syst. Pharmacol."},{"key":"ref_23","unstructured":"United States Food and Drug Administration (2022, September 08). Guidance for Industry: Population Pharmacokinetics, Available online: https:\/\/www.fda.gov\/media\/71364\/download."},{"key":"ref_24","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1007\/s10928-020-09695-z","article-title":"Prior Information for Population Pharmacokinetic and Pharmacokinetic\/Pharmacodynamic Analysis: Overview and Guidance with a Focus on the NONMEM PRIOR Subroutine","volume":"47","author":"Calvier","year":"2020","journal-title":"J. Pharmacokinet. Pharmacodyn."},{"key":"ref_25","doi-asserted-by":"crossref","first-page":"241","DOI":"10.1016\/j.cmpb.2005.04.005","article-title":"PsN-Toolkit\u2014A Collection of Computer Intensive Statistical Methods for Non-Linear Mixed Effect Modeling Using NONMEM","volume":"79","author":"Lindbom","year":"2005","journal-title":"Comput. Methods Programs Biomed."},{"key":"ref_26","doi-asserted-by":"crossref","first-page":"2497","DOI":"10.1111\/bcp.14360","article-title":"Prospective Validation of a Model-informed Precision Dosing Tool for Vancomycin in Intensive Care Patients","volume":"86","author":"Keizer","year":"2020","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_27","doi-asserted-by":"crossref","first-page":"95","DOI":"10.5217\/ir.2019.09167","article-title":"Population Pharmacokinetics of Vedolizumab in Asian and Non-Asian Patients with Ulcerative Colitis and Crohn\u2019s Disease","volume":"19","author":"Okamoto","year":"2021","journal-title":"Intest. Res."},{"key":"ref_28","doi-asserted-by":"crossref","first-page":"2014","DOI":"10.1111\/bcp.14605","article-title":"Population Pharmacokinetic Analysis of Peficitinib in Patients with Rheumatoid Arthritis","volume":"87","author":"Toyoshima","year":"2021","journal-title":"Br. J. Clin. Pharmacol."},{"key":"ref_29","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s13318-021-00681-5","article-title":"Model-Informed Therapeutic Drug Monitoring of Meropenem in Critically Ill Patients: Improvement of the Predictive Ability of Literature Models with the PRIOR Approach","volume":"46","author":"Kwong","year":"2021","journal-title":"Eur. J. Drug Metab. Pharmacokinet."}],"container-title":["Pharmaceutics"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/10\/2089\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,11]],"date-time":"2025-10-11T00:44:22Z","timestamp":1760143462000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.mdpi.com\/1999-4923\/14\/10\/2089"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,9,30]]},"references-count":29,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2022,10]]}},"alternative-id":["pharmaceutics14102089"],"URL":"https:\/\/doi.org\/10.3390\/pharmaceutics14102089","relation":{},"ISSN":["1999-4923"],"issn-type":[{"value":"1999-4923","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,9,30]]}}}